PHARMACOLOGICAL RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2020-10-26 Charlo

10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。

215 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2023-11-13 ms2000000030700368 来自贵州省

这个投稿，必须要每个作者确认么

33 0

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2023-09-18 1487e742m42(暂无昵称) 来自内蒙古

偏重的研究方向：免疫
经验分享：9.12 Submitted to Journal
9.12 2小时后 With Editor
然后，没有动静了。。。

33 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2023-10-17 ms6000001563747786 来自江西省

偏重的研究方向：重症感染
经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗

25 0

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2023-08-08 ms4000001877031685 来自北京

个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。

41 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2023-05-09 Yancie JAY 来自陕西省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤治疗抵抗
经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？

0 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2023-07-09 ms4000000001549833 来自江苏省

Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗

31 0

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2023-06-28 ms9000000127932161 来自福建省

有人遇到提交的时候Declaration of Interest无法提交的问题吗

28 0

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2021-04-25 金鱼的眼泪

4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭

77 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168239, encodeId=71c32168239bc, content=这个投稿，必须要每个作者确认么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30f09061934, createdName=ms2000000030700368, createdTime=Mon Nov 13 11:46:34 CST 2023, time=2023-11-13, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2158267, encodeId=2dbf215826e2d, content=偏重的研究方向：免疫 经验分享：9.12 Submitted to Journal 9.12 2小时后 With Editor 然后，没有动静了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Sep 18 12:05:01 CST 2023, time=2023-09-18, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2163326, encodeId=80fc216332625, content=偏重的研究方向：重症感染 经验分享：请问一篇综述投了Translational research，期刊转投服务给了这个，但我的文章是自噬方向的，投这个合理吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Tue Oct 17 15:06:15 CST 2023, time=2023-10-17, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2151849, encodeId=fd87215184969, content=个人感觉速度确实快，拒稿也很快，投稿第二天就跟我说不再继续进一步审查，建议转投了，估计是拒稿了吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbb8779194, createdName=ms4000001877031685, createdTime=Tue Aug 08 23:22:33 CST 2023, time=2023-08-08, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2131181, encodeId=7709213118195, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤治疗抵抗 经验分享：这个杂志版面费怎么交啊，一月份接收的文章，现在没收到版面费的链接？有大佬知道该咋办吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ab2096768, createdName=Yancie JAY, createdTime=Tue May 09 17:22:19 CST 2023, time=2023-05-09, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2147051, encodeId=f8e9214e05180, content=Pharmacological Research - Modern Chinese Medicine这个期刊什么时候才会有影响因子吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a915704570, createdName=ms4000000001549833, createdTime=Sun Jul 09 00:40:51 CST 2023, time=2023-07-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2145200, encodeId=751b214520084, content=有人遇到提交的时候Declaration of Interest无法提交的问题吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59bb8745305, createdName=ms9000000127932161, createdTime=Wed Jun 28 12:25:04 CST 2023, time=2023-06-28, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069878, encodeId=8ab110698e82e, content=审稿速度:1.0 偏重的研究方向：机制;动物模型;药效 经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7925628265, createdName=ms6000000354139974, createdTime=Sat Nov 13 12:49:03 CST 2021, time=2021-11-13, status=1, ipAttribution=)]

2021-11-13 ms6000000354139974

审稿速度:1.0
偏重的研究方向：机制;动物模型;药效
经验分享：投稿3天under review, 30天审稿人意见回来，充分肯定了我们的研究，提了一条建议和一个问题，当天给了小修，3天后修回，当天马上返回审稿人，3天后接收。审稿还是挺快的，编辑处理也很及时。注重创新，建议大家多投！

72 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务